Atea Pharmaceuticals (NASDAQ:AVIR) Stock: Insider Bruce Polsky Sells 14,254 Shares

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Get Free Report) Director Bruce Polsky sold 14,254 shares of the firm’s stock in a transaction dated Monday, November 16th. The stock was sold at an average price of $4.27, for a total value of $60,864.58. Following the sale, the director directly owned 158,580 shares of the company’s stock, valued at $677,136.60. This trade represents a 8.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Bruce Polsky also recently made the following trade(s):

  • On Wednesday, November 18th, Bruce Polsky sold 18,252 shares of Atea Pharmaceuticals stock. The shares were sold at an average price of $3.95, for a total value of $72,095.40.
  • On Tuesday, November 17th, Bruce Polsky sold 8,720 shares of Atea Pharmaceuticals stock. The shares were sold at an average price of $4.03, for a total value of $35,141.60.

Atea Pharmaceuticals Stock Performance

Shares of NASDAQ AVIR traded up $0.03 during trading hours on Wednesday, hitting $3.99. The stock had a trading volume of 342,250 shares, compared to its average volume of 307,434. The firm’s 50-day moving average price is $4.70 and its two-hundred day moving average price is $4.94. Atea Pharmaceuticals, Inc. has a 52 week low of $2.92 and a 52 week high of $6.45. The company has a market capitalization of $320.40 million, a P/E ratio of -2.05 and a beta of 0.76.

Atea Pharmaceuticals (NASDAQ:AVIR – Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.11. As a group, analysts expect that Atea Pharmaceuticals, Inc. will post -1.60 EPS for the current fiscal year.

Institutional Trading of Atea Pharmaceuticals

Several large investors have recently modified their holdings of the company. Legal & General Group Plc acquired a new position in Atea Pharmaceuticals in the 2nd quarter valued at $33,000. Quantinno Capital Management LP acquired a new position in Atea Pharmaceuticals during the 1st quarter worth $86,000. Spark Investment Management LLC acquired a new position in Atea Pharmaceuticals during the 2nd quarter worth $75,000. Headlands Technologies LLC bought a new stake in Atea Pharmaceuticals during the second quarter valued at about $77,000. Finally, Engineers Gate Manager LP bought a new stake in Atea Pharmaceuticals during the second quarter valued at about $78,000. 86.67% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms have commented on AVIR. Wall Street Zen raised shares of Atea Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, September 12th. Morgan Stanley raised their price target on shares of Atea Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a report on Monday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Atea Pharmaceuticals in a research note on Thursday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $8.00.

Read Our Latest Report on AVIR

About Atea Pharmaceuticals

(Get Free Report)

Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing oral antiviral medicines for serious viral diseases. Its research centers on compounds intended to interfere with viral replication. The company’s investigational portfolio has included bemnifosbuvir, an oral antiviral candidate studied for COVID-19, as well as programs targeting other viral infections, including dengue. These medicines are investigational and are not established marketed treatments.

Featured Articles

Receive News & Ratings for Atea Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atea Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.